La vendita allo scoperto per ProShares S&P Kensho Smart Factories ETF dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di ProShares S&P Kensho Smart Factories ETF. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

ProShares S&P Kensho Smart Factories ETF (ARCA:MAKX), Report sulle vendite allo scoperto

Technology

Industrials

Basic Materials

The Fund invests in financial instruments that ProShare Advisors believes, in combination, should track the performance of the Index. The Index selects companies focused on building the technology empowering the digitalization of manufacturing activities. The Index includes companies focused on products and services that enable factory digitalization.

Ouster Inc

Aspen Technology Inc

Emerson Electric Co

Cognex Corp

Rockwell Automation, Inc

Autodesk Inc

Hollysys Automation Technologies Ltd

3D Systems Corp

Ambarella, Inc.

Sktelecomco.ltd.ADR

Sk Telecom Co Ltd-Spon Adr

Dover Corp

Stratasys Ltd

Faro Technologies Inc

Turkcell Iletisim Hizmet-Adr

Sanmina Corp

Zebra Technologies Corp Cl A

Tower Semiconductor Ltd

On Semiconductor

Proshares S&P Kensho Smart Factories ETF

Businessmen,Making,Handshake,With,Partner,,Greeting,,Dealing,,Merger,And,Acquisition,

Equities

News

Markets

Movers

General

AMZN

MAKX

L&#39;accordo tra le due aziende spinge verso l&#39;alto il titolo. Analisi degli impatti, le soluzioni e il futuro del settore manifatturiero.

Azioni Rockwell in rialzo: la partnership con Amazon scuote il mercato

ProShares S&P Kensho Smart Factories ETF

Macro Economic Events

Politics

Global

Economics

Reuters Reports Japan's Trade Negotiator Akazawa Had Phone Call With U.S. Treasury Secretary Bessent; U.S., Japan Agreed To Continue Vigorous Talks On Tariffs; Japan Continues To Seek Mutually Beneficial Agreement With U.S.

<p>Cantor Fitzgerald  analyst Colin Canfield   initiates coverage on AIRO Group Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRO#NASDAQ">AIRO</a>) with a Overweight rating and announces Price Target of $35.</p>


Price Target

Initiation

Analyst Ratings

AIRO

Cantor Fitzgerald Initiates Coverage On AIRO Group Holdings with Overweight Rating, Announces Price Target of $35

<p><strong>Elon Musk</strong> has roasted his fair share of billionaires, but his <a href="https://www.benzinga.com/news/25/05/45484920/more-than-a-feud-elon-musk-bill-gates-spat-sheds-light-on-competing-views-of-efficiency">ongoing feud with <strong>Bill Gates</strong></a> might be the pettiest — and most expensive — of them all.</p>
<p>According to Musk, the Microsoft co-founder didn't just short Tesla stock behind his back — he allegedly tried to profit off the company's collapse. Then, with perfect timing, Gates asked Musk to support his climate philanthropy. Musk's reaction? "Boggles the mind."</p>
<p>"The lack of self-awareness and hypocrisy of Gates who had the nerve to ask me to donate to his mostly window-dressing environmental causes," <a href="https://x.com/elonmusk/status/1701342980114706613">Musk posted on X</a>, "while simultaneously aiming to make $500M from Tesla's demise, boggles the mind…"</p>
<p><strong>Don't Miss:</strong></p>
<ul class="wp-block-list">
<li><strong>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"><strong> </strong><strong>Here&#8217;s how you can earn passive income with just $10.</strong></a></strong></li>
<li><strong>$100k+ in investable assets? <a href="https://www.benzinga.com/money/wiseradvisor-retirement-planning"><strong>Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes</strong></a> – no cost, no obligation.</strong></li>
</ul>
<p>Musk wasn't done. "Gates placed a massive bet on Tesla dying when our company was at one of its weakest moments," he continued. "To the best of my knowledge, Gates still has that massive bet against Tesla on the table. Someone should ask him if he does."</p>
<p>The $500 million figure wasn't pulled from thin air. According to biographer <strong>Walter Isaacson</strong>, Gates placed the short years earlier, and by the time of a <a href="https://www.cnn.com/2023/09/11/tech/elon-musk-bill-gates-isaacson-book">2022 meeting with Musk</a> at Tesla's Austin Texas gigafactory, he had already lost between $1.5 billion and $2 billion.</p>
<p>Gates reportedly apologized — and later told Isaacson, "Once he heard I'd shorted the stock, <a href="https://www.benzinga.com/25/02/43880898/im-in-awe-bill-gates-says-elon-musk-is-brilliant-rich-and-influential-but-admits-hes-been-mean-to-me-at-times">he was super mean to me</a>. But he's super mean to so many people, so you can't take it too personally."</p>
<p><strong>Trending: BlackRock is calling 2025 the year of alternative assets. <a href="https://www.benzinga.com/money/masterworks"><strong>One firm from NYC has quietly built a group of 60,000+ investors who have all joined in on an alt asset class previously exclusive to billionaires like Bezos and Gates.</strong></a></strong></p>
<p>Musk didn't exactly send back a fruit basket. After that meeting, he texted Isaacson:</p>
<p>"At this point, I am convinced that he is categorically insane (and an a–hole to the core). I did actually want to like him (sigh)."</p>
<p>This wasn't the first time the two billionaires butted heads. In 2020, <a href="https://www.benzinga.com/25/05/45305930/elon-musk-said-bill-gates-has-no-clue-after-gates-claimed-electric-trucks-may-never-be-practical-because-they-cant-cover-long-distances">Musk said Gates "has no clue" about electric trucks</a> after Gates chose a Porsche Taycan over a Tesla. Gates later jabbed back in a <a href="https://www.cnbc.com/2020/09/18/bill-gates-difference-between-elon-musk-and-steve-jobs-as-leaders.html">CNBC interview</a>, saying Musk's "rockets work well" but his "level of outrageous comments" is part of the brand.</p>
<p>So far, Gates hasn't publicly confirmed whether he still holds a short position on Tesla. But Musk seems to think he does — and he hasn't exactly let it go. In a <a href="https://x.com/elonmusk/status/1808156026123829599">post on X in July 2024, Musk warned</a>: "Once Tesla fully solves autonomy and has Optimus in volume production, anyone still holding a short position will be obliterated. Even Gates."</p>
<p><strong>Read Next:&nbsp;</strong></p>
<ul class="wp-block-list">
<li><strong><a href="https://www.benzinga.com/money/mark-cubans-advice-for-lotto-winners">Many are surprised by Mark Cuban's advice for lotto winners: Cash or annuity?</a></strong></li>
<li><strong>Over the last five years, the price of gold has increased by approximately 83% — Investors like Bill O&#8217;Reilly and Rudy Giuliani are using this platform to <a href="https://www.benzinga.com/money/american-hartford-gold"><strong>create customized gold IRAs to help shield their savings from inflation and economic turbulence. </strong></a></strong></li>
</ul>
<p><em><strong>Images via Shutterstock</strong></em></p>


Personal Finance

Elon Musk Says Bill Gates Bet $500 Million on Tesla's Demise Then Had the 'Nerve' To Ask Him for a Donation — 'Boggles the Mind'

<p>Financial giants have made a conspicuous bullish move on American Airlines Group. Our analysis of options history for American Airlines Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>) revealed 8 unusual trades.</p>
<p>Delving into the details, we found 75% of traders were bullish, while 25% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $105,035, and 5 were calls, valued at $261,791.</p>
<h3>Predicted Price Range</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $8.0 to $12.0 for American Airlines Group over the recent three months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for American Airlines Group's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of American Airlines Group's whale trades within a strike price range from $8.0 to $12.0 in the last 30 days. </p>
<h3>American Airlines Group Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1751983274_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>AAL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$1.72</td>
<td>$1.68</td>
<td>$1.7</td>
<td>$12.00</td>
<td>$102.1K</td>
<td>33.9K</td>
<td>986</td>
</tr>
<tr>
<td>AAL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$1.7</td>
<td>$1.67</td>
<td>$1.7</td>
<td>$12.00</td>
<td>$51.0K</td>
<td>33.9K</td>
<td>1.4K</td>
</tr>
<tr>
<td>AAL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$1.7</td>
<td>$1.67</td>
<td>$1.7</td>
<td>$12.00</td>
<td>$51.0K</td>
<td>33.9K</td>
<td>385</td>
</tr>
<tr>
<td>AAL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$1.76</td>
<td>$1.58</td>
<td>$1.58</td>
<td>$12.00</td>
<td>$46.6K</td>
<td>57.3K</td>
<td>1.1K</td>
</tr>
<tr>
<td>AAL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$1.7</td>
<td>$1.69</td>
<td>$1.69</td>
<td>$12.00</td>
<td>$31.6K</td>
<td>33.9K</td>
<td>1.1K</td>
</tr>
</tbody>
</table>
</p>
<h3>About American Airlines Group</h3>
<p>American Airlines is the world's largest airline by aircraft, capacity, and scheduled revenue passenger miles. Its major US hubs are Charlotte, Chicago, Dallas/Fort Worth, Los Angeles, Miami, New York, Philadelphia, Phoenix, and Washington, D.C. It generates over 30% of US airline revenue connecting Latin America with destinations in the United States. After completing a major fleet renewal, the company has the youngest fleet of US legacy carriers.</p>
<h3>Present Market Standing of American Airlines Group</h3>
<ul>
<li>With a volume of 3,865,159, the price of AAL is up 2.33% at $11.86. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 16 days.</li>
</ul>
<h3>What Analysts Are Saying About American Airlines Group</h3>
<p>Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $12.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from B of A Securities persists with their Neutral rating on American Airlines Group, maintaining a target price of $12.<br />
&#x2A; An analyst from UBS persists with their Neutral rating on American Airlines Group, maintaining a target price of $12. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest American Airlines Group options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


Options

Check Out What Whales Are Doing With AAL

<p>Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Stryker, revealing an average target of $423.2, a high estimate of $456.00, and a low estimate of $390.00. This upward trend is evident, with the current average reflecting a 4.34% increase from the previous average price target of $405.60.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1751983271_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>The perception of Stryker by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$415.00</td>
<td>$390.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$455.00</td>
<td>$443.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$400.00</td>
<td>$390.00</td>
</tr>
<tr>
<td>Jason Wittes</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Buy</td>
<td>$456.00</td>
<td>$405.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$390.00</td>
<td>$400.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Stryker. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Stryker compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Stryker's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SYK/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Stryker analyst ratings.</strong></a></p>
<h2>Delving into Stryker's Background</h2>
<p>Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Roughly one fourth of Stryker's total revenue currently comes from outside the United States.</p>
<h3>Stryker's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization:</strong> Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.</p>
<p><strong>Revenue Growth:</strong> Stryker displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately <strong>11.88%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>11.15%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>3.15%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Stryker's ROA excels beyond industry benchmarks, reaching <strong>1.47%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.8</strong>.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


The Analyst Verdict: Stryker In The Eyes Of 5 Experts

<p>Deep-pocketed investors have adopted a bullish approach towards Enovix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVX#NASDAQ">ENVX</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in ENVX usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 16 extraordinary options activities for Enovix. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 56% leaning bullish and 37% bearish. Among these notable options, 7 are puts, totaling $721,461, and 9 are calls, amounting to $423,389.</p>
<h3>Projected Price Targets</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $8.0 and $23.0 for Enovix, spanning the last three months.</p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for Enovix options trades today is 2689.43 with a total volume of 15,081.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Enovix's big money trades within a strike price range of $8.0 to $23.0 over the last 30 days.</p>
<h3>Enovix 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1751983269_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ENVX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$1.94</td>
<td>$1.75</td>
<td>$1.75</td>
<td>$12.00</td>
<td>$442.5K</td>
<td>43</td>
<td>2.5K</td>
</tr>
<tr>
<td>ENVX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$5.0</td>
<td>$4.9</td>
<td>$4.9</td>
<td>$10.00</td>
<td>$114.6K</td>
<td>15.5K</td>
<td>0</td>
</tr>
<tr>
<td>ENVX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$9.65</td>
<td>$8.9</td>
<td>$9.65</td>
<td>$23.00</td>
<td>$96.5K</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>ENVX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/17/25</td>
<td>$2.51</td>
<td>$0.01</td>
<td>$0.62</td>
<td>$8.00</td>
<td>$62.0K</td>
<td>2.3K</td>
<td>2.0K</td>
</tr>
<tr>
<td>ENVX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/20/26</td>
<td>$5.95</td>
<td>$4.75</td>
<td>$5.3</td>
<td>$10.00</td>
<td>$53.0K</td>
<td>663</td>
<td>100</td>
</tr>
</tbody>
</table>
</p>
<h3>About Enovix</h3>
<p>Enovix Corp is engaged in designing, developing, manufacturing, and commercializing Lithium-ion, or Li-ion, battery cells. It uses BreakFlow and Encapsulation technologies to manufacture high capacity and resilient batteries. The company's product portfolio comprises power disc batteries, flexible lithium-ion polymer batteries, superior lithium-ion polymer batteries, active silicon lithium-ion cells, and others. Geographically, the company generates maximum revenue from its customers in South Korea, followed by Switzerland, Norway, the United States, Taiwan, and other regions.</p>
<p>Following our analysis of the options activities associated with Enovix, we pivot to a closer look at the company's own performance.</p>
<h3>Enovix's Current Market Status</h3>
<ul>
<li>Trading volume stands at 3,369,724, with ENVX's price up by 4.6%, positioned at $13.63.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 22 days.</li>
</ul>
<h3>Expert Opinions on Enovix</h3>
<p>Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $15.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Craig-Hallum persists with their Buy rating on Enovix, maintaining a target price of $15. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Enovix, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


ENVX

Enovix's Options: A Look at What the Big Money is Thinking

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Citigroup</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with C, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 16 uncommon options trades for Citigroup.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 68% bullish and 31%, bearish.</p>
<p>Out of all of the special options we uncovered, 2 are puts, for a total amount of $203,581, and 14 are calls, for a total amount of $12,929,590.</p>
<h3>Predicted Price Range</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $60.0 and $87.5 for Citigroup, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Citigroup's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Citigroup's whale activity within a strike price range from $60.0 to $87.5 in the last 30 days. </p>
<h3>Citigroup Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1751983264_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>C</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/17/27</td>
<td>$21.25</td>
<td>$20.4</td>
<td>$20.5</td>
<td>$75.00</td>
<td>$11.0M</td>
<td>7.8K</td>
<td>7.3K</td>
</tr>
<tr>
<td>C</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/17/27</td>
<td>$20.65</td>
<td>$20.4</td>
<td>$20.65</td>
<td>$75.00</td>
<td>$687.6K</td>
<td>7.8K</td>
<td>1.5K</td>
</tr>
<tr>
<td>C</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/17/27</td>
<td>$20.75</td>
<td>$20.7</td>
<td>$20.75</td>
<td>$75.00</td>
<td>$456.5K</td>
<td>7.8K</td>
<td>214</td>
</tr>
<tr>
<td>C</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/17/27</td>
<td>$20.65</td>
<td>$20.6</td>
<td>$20.65</td>
<td>$75.00</td>
<td>$212.7K</td>
<td>7.8K</td>
<td>1.9K</td>
</tr>
<tr>
<td>C</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$4.85</td>
<td>$4.8</td>
<td>$4.81</td>
<td>$82.50</td>
<td>$146.7K</td>
<td>2.5K</td>
<td>165</td>
</tr>
</tbody>
</table>
</p>
<h3>About Citigroup</h3>
<p>Citigroup is a global financial-services company doing business in more than 100 countries and jurisdictions. Citigroup's operations are organized into five primary segments: services, markets, banking, US personal banking, and wealth management. The bank's primary services include cross-border banking needs for multinational corporates, investment banking and trading, and credit card services in the United States.</p>
<p>In light of the recent options history for Citigroup, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Current Position of Citigroup</h3>
<ul>
<li>Trading volume stands at 1,075,211, with C's price down by -0.68%, positioned at $87.0.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 7 days.</li>
</ul>
<h3>Professional Analyst Ratings for Citigroup</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $91.8.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Morgan Stanley keeps a Overweight rating on Citigroup with a target price of $94.<br />
&#x2A; An analyst from B of A Securities has decided to maintain their Buy rating on Citigroup, which currently sits at a price target of $100.<br />
&#x2A; An analyst from Goldman Sachs persists with their Buy rating on Citigroup, maintaining a target price of $85.<br />
&#x2A; An analyst from Evercore ISI Group persists with their In-Line rating on Citigroup, maintaining a target price of $77.<br />
&#x2A; An analyst from Morgan Stanley has decided to maintain their Overweight rating on Citigroup, which currently sits at a price target of $103. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Citigroup options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


Looking At Citigroup's Recent Unusual Options Activity

<p>Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $129.0, along with a high estimate of $145.00 and a low estimate of $120.00. Surpassing the previous average price target of $123.83, the current average has increased by 4.18%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1751983261_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Morgan Stanley by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Whit Mayo</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$145.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Keith Horowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$130.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Richard Ramsden</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$136.00</td>
<td>$121.00</td>
</tr>
<tr>
<td>Richard Ramsden</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$121.00</td>
<td>$122.00</td>
</tr>
<tr>
<td>Kian Abouhossein</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$122.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Whit Mayo</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$120.00</td>
<td>$130.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Morgan Stanley. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Morgan Stanley compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Morgan Stanley's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Morgan Stanley's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/MS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Morgan Stanley analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Morgan Stanley</h2>
<p>Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments with approximately 45% of net revenue from its institutional securities business, 45% from wealth management, and 10% from investment management. About 24% of its total revenue is from outside the Americas. The company had over $6 trillion of client assets as well as around 70,000 employees at the end of 2024.</p>
<h3>Understanding the Numbers: Morgan Stanley's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.</p>
<p><strong>Revenue Growth:</strong> Morgan Stanley displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately <strong>16.19%</strong>. This indicates a notable increase in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Morgan Stanley's net margin is impressive, surpassing industry averages. With a net margin of <strong>25.17%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Morgan Stanley's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>4.33%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Morgan Stanley's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>0.33%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Morgan Stanley's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>3.38</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


A Glimpse Into The Expert Outlook On Morgan Stanley Through 6 Analysts

<p>Target Hospitality (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TH#NASDAQ">TH</a>) is gearing up to announce its quarterly earnings on Monday, 2025-05-19. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Target Hospitality will report an <strong>earnings per share</strong> (EPS) of $-0.02.</p>
<p>Anticipation surrounds Target Hospitality's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Historical Earnings Performance</h3>
<p>The company's EPS beat by $0.05 in the last quarter, leading to a 3.07% increase in the share price on the following day.</p>
<p>Here's a look at Target Hospitality's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.02</td>
<td>0.07</td>
<td>0.12</td>
<td>0.17</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.07</td>
<td>0.12</td>
<td>0.20</td>
<td>0.18</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-3.0%</td>
<td>3.0%</td>
<td>-0.0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1751983259_0.png" alt="eps graph" /></p>
<h3>Market Performance of Target Hospitality's Stock</h3>
<p>Shares of Target Hospitality were trading at $7.6 as of July 07. Over the last 52-week period, shares are down 11.11%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/TH/earnings"><strong>To track all earnings releases for Target Hospitality visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings

What's Next: Target Hospitality's Earnings Preview

<p>Ratings for Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) were provided by 11 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Zimmer Biomet Holdings, revealing an average target of $106.36, a high estimate of $125.00, and a low estimate of $95.00. Experiencing a 13.01% decline, the current average is now lower than the previous average price target of $122.27. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1751983250_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>A clear picture of Zimmer Biomet Holdings's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$96.00</td>
<td>$102.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$101.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>David Turkaly</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$125.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$104.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$104.00</td>
<td>$119.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$115.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$112.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Cecilia Furlong</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$95.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$105.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$98.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$115.00</td>
<td>$130.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Zimmer Biomet Holdings. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Zimmer Biomet Holdings compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Zimmer Biomet Holdings's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>For valuable insights into Zimmer Biomet Holdings's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ZBH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Zimmer Biomet Holdings analyst ratings.</strong></a></p>
<h2>All You Need to Know About Zimmer Biomet Holdings</h2>
<p>Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.</p>
<h3>Zimmer Biomet Holdings's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Over the 3M period, Zimmer Biomet Holdings showcased positive performance, achieving a revenue growth rate of <strong>1.05%</strong> as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>9.53%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Zimmer Biomet Holdings's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>1.46%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Zimmer Biomet Holdings's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>0.84%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> Zimmer Biomet Holdings's debt-to-equity ratio is below the industry average. With a ratio of <b>0.58</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Breaking Down Zimmer Biomet Holdings: 11 Analysts Share Their Views

<p>Theratechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THTX#NASDAQ">THTX</a>) is gearing up to announce its quarterly earnings on Wednesday, 2025-07-09. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Theratechnologies will report an <strong>earnings per share</strong> (EPS) of $0.00.</p>
<p>The announcement from Theratechnologies is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Historical Earnings Performance</h3>
<p>In the previous earnings release, the company missed EPS by $0.00, leading to a 6.34% drop in the share price the following trading session.</p>
<p>Here's a look at Theratechnologies's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0</td>
<td>0</td>
<td>0.03</td>
<td>-0.02</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0</td>
<td>-0.16</td>
<td>0.06</td>
<td>0.02</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-6.0%</td>
<td>1.0%</td>
<td>-1.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1751983249_0.png" alt="eps graph" /></p>
<h3>Theratechnologies Share Price Analysis</h3>
<p>Shares of Theratechnologies were trading at $3.17 as of July 07. Over the last 52-week period, shares are up 110.0%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/THTX/earnings"><strong>To track all earnings releases for Theratechnologies visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


THTX

A Look at Theratechnologies's Upcoming Earnings Report

WIIM

BSGM

BSGM stock has given up its prior gain. BigSig Technologies shares were trading higher after the company announced it generated $1.1 billion in financing to launch a gold-backed treasury strategy and RWA tokenization platform.

<p>Methode Electronics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MEI#NYSE">MEI</a>) is preparing to release its quarterly earnings on Wednesday, 2025-07-09. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Methode Electronics to report an <strong>earnings per share</strong> (EPS) of $0.12.</p>
<p>Anticipation surrounds Methode Electronics's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Overview of Past Earnings</h3>
<p>Last quarter the company missed EPS by $0.13, which was followed by a 28.92% drop in the share price the next day.</p>
<p>Here's a look at Methode Electronics's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2025</strong></th>
<th><strong>Q2 2025</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.08</td>
<td>-0.16</td>
<td>-0.30</td>
<td>-0.20</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.21</td>
<td>0.14</td>
<td>-0.31</td>
<td>-0.23</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-28.999999999999996%</td>
<td>-9.0%</td>
<td>-6.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1751983243_0.png" alt="eps graph" /></p>
<h3>Performance of Methode Electronics Shares</h3>
<p>Shares of Methode Electronics were trading at $10.07 as of July 07. Over the last 52-week period, shares are up 11.6%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Observations about Methode Electronics</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Methode Electronics.</p>
<p>Analysts have provided Methode Electronics with 1 ratings, resulting in a consensus rating of Neutral. The average one-year price target stands at $7.0, suggesting a potential 30.49% downside.</p>
<h3>Comparing Ratings with Peers</h3>
<p>This comparison focuses on the analyst ratings and average 1-year price targets of Data I/O, Benchmark Electronics and IPG Photonics, three major players in the industry, shedding light on their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for Data I/O, with an average 1-year price target of $5.22, suggesting a potential 48.16% downside.</li>
<li>Analysts currently favor an Buy trajectory for Benchmark Electronics, with an average 1-year price target of $47.0, suggesting a potential 366.73% upside.</li>
<li>Analysts currently favor an Buy trajectory for IPG Photonics, with an average 1-year price target of $70.0, suggesting a potential 595.13% upside.</li>
</ul>
<h3>Peer Metrics Summary</h3>
<p>The peer analysis summary outlines pivotal metrics for Data I/O, Benchmark Electronics and IPG Photonics, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methode Electronics</td>
<td>Neutral</td>
<td>-7.55%</td>
<td>$41.30M</td>
<td>-2.00%</td>
</tr>
<tr>
<td>Data I/O</td>
<td>Buy</td>
<td>1.26%</td>
<td>$3.19M</td>
<td>-2.17%</td>
</tr>
<tr>
<td>Benchmark Electronics</td>
<td>Buy</td>
<td>-6.49%</td>
<td>$63.18M</td>
<td>0.33%</td>
</tr>
<tr>
<td>IPG Photonics</td>
<td>Buy</td>
<td>-9.61%</td>
<td>$89.81M</td>
<td>0.18%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Methode Electronics ranks at the bottom for Revenue Growth among its peers. It also ranks at the bottom for Gross Profit. However, it ranks at the top for Return on Equity. Overall, Methode Electronics is positioned in the middle compared to its peers based on the provided metrics.</p>
<h3>Discovering Methode Electronics: A Closer Look</h3>
<p>Methode Electronics Inc makes component and subsystem devices employing electrical, radio remote control, electronic, wireless, and sensing technologies. The firm is organized into various business segments: Automotive, Industrial, Interface, and Medical. The Automotive segment which generates maximum revenue, supplies electronic and electro-mechanical devices and related products to automobiles. The products manufactured in the automotive segment include overhead and center consoles, hidden and ergonomic switches, insert molded components, LED-based lighting, and sensors. Geographically, the company generates maximum revenue from North America and the rest from Europe, the Middle East &amp; Africa (EMEA), and Asia.</p>
<h3>Methode Electronics's Financial Performance</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Methode Electronics's financials over 3 months reveals challenges. As of 31 January, 2025, the company experienced a decline of approximately <strong>-7.55%</strong> in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>-6.0%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Methode Electronics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-2.0%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Methode Electronics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-1.07%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> Methode Electronics's debt-to-equity ratio is below the industry average at <strong>0.5</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<p><a href="https://www.benzinga.com/quote/MEI/earnings"><strong>To track all earnings releases for Methode Electronics visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Methode Electronics Earnings Preview

<p>6 analysts have expressed a variety of opinions on Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $9.37, a high estimate of $12.00, and a low estimate of $8.50. Observing a 0.43% increase, the current average has risen from the previous average price target of $9.33. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1751983239_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The standing of Sage Therapeutics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>George Farmer</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$9.20</td>
<td>$12.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$9.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$8.50</td>
<td>$9.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$9.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Sumant Kulkarni</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Hold</td>
<td>$8.50</td>
<td>$8.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Sage Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Sage Therapeutics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Sage Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Sage Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SAGE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Sage Therapeutics analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>Unveiling the Story Behind Sage Therapeutics</h2>
<p>Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.</p>
<h3>Understanding the Numbers: Sage Therapeutics's Finances</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Sage Therapeutics's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of <strong>77.97%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Sage Therapeutics's net margin excels beyond industry benchmarks, reaching <strong>-442.39%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Sage Therapeutics's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>-14.22%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Sage Therapeutics's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-12.24%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Sage Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.03</strong>.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


SAGE

Beyond The Numbers: 6 Analysts Discuss Sage Therapeutics Stock

<p><strong>HealthEquity's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NYSE">HQY</a>) short percent of float has fallen 11.68% since its last report. The company recently reported that it has <strong>5.26 million shares sold short</strong>, which is 7.03% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 3.6 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>List of the most shorted stocks</strong></a></p>
<h3>HealthEquity Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1751983232_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for HealthEquity has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing HealthEquity's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, HealthEquity's peer group average for short interest as a percentage of float is 4.49%, which means the company has <strong>more</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Sellers

Short Ideas

Trading Ideas

How Is The Market Feeling About HealthEquity?

<p>Ratings for Ferguson Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FERG#NYSE">FERG</a>) were provided by 12 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">10</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $225.17, with a high estimate of $280.00 and a low estimate of $190.00. This upward trend is apparent, with the current average reflecting a 16.78% increase from the previous average price target of $192.82.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1751983230_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Ferguson Enterprises. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sam Reid</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$250.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Suhasini Varanasi</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Buy</td>
<td>$280.00</td>
<td>-</td>
</tr>
<tr>
<td>Annelies Vermeulen</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$220.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Patrick Baumann</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$220.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Scott Schneeberger</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$235.00</td>
<td>$189.00</td>
</tr>
<tr>
<td>Mike Dahl</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$231.00</td>
<td>$189.00</td>
</tr>
<tr>
<td>John Lovallo</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$204.00</td>
<td>$173.00</td>
</tr>
<tr>
<td>Sam Reid</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$230.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Matthew Bouley</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$247.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Annelies Vermeulen</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$195.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Patrick Baumann</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$200.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Sam Reid</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$190.00</td>
<td>$180.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Ferguson Enterprises. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Ferguson Enterprises compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Ferguson Enterprises's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Ferguson Enterprises's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/FERG/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Ferguson Enterprises analyst ratings.</strong></a></p>
<h2>About Ferguson Enterprises</h2>
<p>Ferguson distributes plumbing and HVAC products to North American repair, maintenance and improvement, new construction, and civil infrastructure markets. It serves over 1 million customers and sources products from 36,000 suppliers. Ferguson engages customers through approximately 1,800 North American branches, over the phone, online, and in residential showrooms. According to Modern Distribution Management, Ferguson is the largest plumbing distributor and second-largest HVAC distributor (next to Watsco) in North America. The firm sold its UK business in 2021 and is now solely focused on the North American market.</p>
<h3>Understanding the Numbers: Ferguson Enterprises's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.</p>
<p><strong>Revenue Growth:</strong> Ferguson Enterprises displayed positive results in 3M. As of 30 April, 2025, the company achieved a solid revenue growth rate of approximately <strong>4.28%</strong>. This indicates a notable increase in the company's top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Ferguson Enterprises's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>5.38%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Ferguson Enterprises's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>7.44%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Ferguson Enterprises's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>2.43%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Ferguson Enterprises's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>1.05</strong>.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


FERG

Deep Dive Into Ferguson Enterprises Stock: Analyst Perspectives (12 Ratings)

<p>Bassett Furniture Indus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSET#NASDAQ">BSET</a>) is gearing up to announce its quarterly earnings on Wednesday, 2025-07-09. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Bassett Furniture Indus will report an <strong>earnings per share</strong> (EPS) of $0.15.</p>
<p>The announcement from Bassett Furniture Indus is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Earnings History Snapshot</h3>
<p>In the previous earnings release, the company beat EPS by $0.18, leading to a 1.54% drop in the share price the following trading session.</p>
<p>Here's a look at Bassett Furniture Indus's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.03</td>
<td>-0.01</td>
<td>-0.38</td>
<td>-0.11</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.21</td>
<td>0.38</td>
<td>-0.52</td>
<td>-0.82</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-2.0%</td>
<td>3.0%</td>
<td>-5.0%</td>
<td>5.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1751983229_0.png" alt="eps graph" /></p>
<h3>Tracking Bassett Furniture Indus's Stock Performance</h3>
<p>Shares of Bassett Furniture Indus were trading at $17.19 as of July 07. Over the last 52-week period, shares are up 26.88%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/BSET/earnings"><strong>To track all earnings releases for Bassett Furniture Indus visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


BSET

What to Expect from Bassett Furniture Indus's Earnings

<p><strong>Plug Power's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NYSE">PLUG</a>) short percent of float has risen 5.56% since its last report. The company recently reported that it has <strong>238.13 million shares sold short</strong>, which is 20.89% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 1.81 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>List of the most shorted stocks</strong></a></p>
<h3>Plug Power Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1751983226_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Plug Power has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing Plug Power's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Plug Power's peer group average for short interest as a percentage of float is 13.46%, which means the company has <strong>more</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


PLUG

Is Plug Power Gaining or Losing Market Support?

<p>In the current market session, <strong>Himalaya Shipping Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSHP#NYSE">HSHP</a>)</strong> share price is at $6.24, after a <strong>1.42%</strong> decrease. Over the past month, the stock went up by <strong>1.20%</strong>, but over the past year, it actually fell by <strong>24.91%</strong>. With good short-term performance like this, and questionable long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio.</p>
<p>
</p><p><img src="https://www.benzinga.com/files/images/story/2025/1751983221_0_1.png" alt="Past Year Chart" /></p>

<h3>How Does Himalaya Shipping P/E Compare to Other Companies?</h3>
<p>The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. </p>
<p>Compared to the aggregate P/E ratio of <strong>12.92</strong> in the Marine Transportation industry, Himalaya Shipping Inc. has a higher P/E ratio of <strong>22.61</strong>. Shareholders might be inclined to think that Himalaya Shipping Inc. might perform better than its industry group. It's also possible that the stock is overvalued. </p>
<p>
</p><p><img src="https://www.benzinga.com/files/images/story/2025/1751983221_1.png" alt="Guage" /></p>

<p>In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions. </p>


Intraday Update

HSHP

Price Over Earnings Overview: Himalaya Shipping

<p>Across the recent three months, 9 analysts have shared their insights on American Tower (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMT#NYSE">AMT</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $248.22, a high estimate of $260.00, and a low estimate of $234.00. This current average reflects an increase of 4.54% from the previous average price target of $237.44. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1751983222_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive American Tower. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Batya Levi</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$260.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Jonathan Atkin</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$250.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Gregory Williams</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$241.00</td>
<td>$239.00</td>
</tr>
<tr>
<td>Maher Yaghi</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$248.00</td>
<td>$234.00</td>
</tr>
<tr>
<td>Eric Luebchow</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$240.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Greg Miller</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$260.00</td>
<td>$248.00</td>
</tr>
<tr>
<td>Ric Prentiss</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$251.00</td>
<td>$231.00</td>
</tr>
<tr>
<td>Batya Levi</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$250.00</td>
<td>$245.00</td>
</tr>
<tr>
<td>Maher Yaghi</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$234.00</td>
<td>$220.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to American Tower. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of American Tower compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of American Tower's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into American Tower's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/AMT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on American Tower analyst ratings.</strong></a></p>
<h2>Get to Know American Tower Better</h2>
<p>American Tower owns and operates more than 220,000 cell towers throughout the US, Asia, Latin America, Europe, and Africa. It also owns and/or operates 28 data centers in 10 US markets after acquiring CoreSite. On its towers, the company has a very concentrated customer base, with most revenue in each market being generated by just the top few mobile carriers. The company operates more than 40,000 towers in the US, which accounted for almost half of the company's total revenue in 2023. Outside the US, American Tower operates over 75,000 towers in India, almost 50,000 towers in Latin America (dominated by Brazil), 30,000 towers in Europe, and nearly 25,000 towers in Africa. American Tower operates as a REIT.</p>
<h3>American Tower: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.</p>
<p><strong>Revenue Growth:</strong> Over the 3M period, American Tower showcased positive performance, achieving a revenue growth rate of <strong>2.0%</strong> as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Real Estate sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>19.07%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> American Tower's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>14.13%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> American Tower's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>0.79%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> American Tower's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>12.56</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Comments

ProShares S&P Kensho Smart Factories ETF

Vendite allo scoperto

ProShares S&P Kensho Smart Factories ETF (ARCA:MAKX), Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO